My GBM Story: Meredith, a long-term survivor 

I was diagnosed 6/1/2005 with a 7 cm anomaly. I had my first craniotomy on 6/15/2005 in Atlanta and received the pathology of GBM IV. Slides were sent to four different hospitals and we got varying results from a high AA (3-3+) to a solid GBM (IV). Since the first neurosurgeon in Atlanta was unable to fully resect the tumor, Duke’s Brain Tumor Center did the “redo” and did a full resection 7/15/2005 (one month later). Subsequently, I did a clinical trial for a brain infusion of IL13 (interleukin 13). I did what was standard radiation at that time at Duke, as part of the terms of participating in the clinical trial there.

In 2006, I followed-up under Duke’s care for chemotherapy, using a local oncologist to administer. I did a quarterly rotational regime of Temadar only, Gleevac, Temadar + drug (forget name) , and CPT11 + Avastin. Obviously, this drug regime is not what is standard today, but was more cutting edge in 2006.

I also did an extremely large dose of Tamoxifen in 2007 with little to no side effects, at that time and was able to work at full capacity. 

 

OurBrainBank is extremely important so that we can monitor and track the data from people that are going through GBM, in order to build a bigger set of data, in order to better understand this disease, so that future patients can benefit from us.

I have no known major side-effects from the diagnosis and treatment, no recurrences, and live a normal life of a mom, spouse and business owner. 

OurBrainBank is extremely important so that we can monitor and track the data from people that are going through GBM, in order to build a bigger set of data, in order to better understand this disease, so that future patients can benefit from us.

— Meredith Moore, OurBrainBank board member